Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation
Inflammatory markers associated with development of diabetes in people taking HIV therapy
Maraviroc fails to match tenofovir/emtricitabine for first-line HIV treatment
Protease inhibitor therapy increases underlying genetic risk of diabetes for women with HIV
Risk score can help predict which people living with HIV have highest risk of kidney disease during tenofovir treatment
Heart attack link to abacavir persists in D:A:D study
Raltegravir has the edge over two protease inhibitors in three-drug comparison study
HIV increases fracture risk, say Danes
Dual therapy with Kaletra and 3TC works well regardless of viral load
